A Phase I Study of Ceritinib (LDK378), a Novel ALK Inhibitor, in Combination With Gemcitabine-Based Chemotherapy in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 22 Jun 2018
At a glance
- Drugs Ceritinib (Primary) ; Cisplatin; Gemcitabine; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer; Solid tumours
- Focus Adverse reactions
- 14 Jun 2018 Planned End Date changed from 11 Jun 2018 to 11 Dec 2018.
- 14 Jun 2018 Planned primary completion date changed from 11 May 2018 to 11 Nov 2018.
- 20 Feb 2018 Planned primary completion date changed from 11 Feb 2018 to 11 May 2018.